Tumoral PD-L1 expression in desmoplastic melanoma is associated with depth of invasion, tumor-infiltrating CD8 cytotoxic lymphocytes and the mixed cytomorphological variant

Modern Pathology

Volumn 30, Issue 3, 2017, Pages 357-369

  Frydenlund, Noah ^a   Leone, Dominick ^b   Yang, Shi ^c   Hoang, Mai P ^d   Deng, April ^e   Hernandez Perez, Marier ^f   Singh, Rajendra ^g   Biswas, Asok ^h   Yaar, Ron ⁱ   Mahalingam, Meera ^j  

^a UNIVERSITY OF IOWA   (United States)

^b BOSTON UNIVERSITY   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e UNIVERSITY OF MASSACHUSETTS   (United States)

^f MIRACA LIFE SCIENCES   (United States)

^g MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^h WESTERN GENERAL HOSPITAL   (United Kingdom)

ⁱ Aurora Diagnostics GPA Laboratories   (United States)

^j Department of Pathology and Laboratory Medicine   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 2; CD274 PROTEIN, HUMAN;

ARTICLE; CANCER PATIENT; CELL INFILTRATION; CELL STRUCTURE; CYTOTOXIC LYMPHOCYTE; DESMOPLASTIC MELANOMA; FEMALE; GENETIC VARIABILITY; HEALTH STATUS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PERINEURAL INVASION; PRIORITY JOURNAL; PROMOTER REGION; TISSUE SECTION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR INVASION; TUMOR MICROENVIRONMENT; TUMOR VOLUME; AGED; CASE CONTROL STUDY; CD8+ T LYMPHOCYTE; IMMUNOLOGY; MELANOMA; METABOLISM; MIDDLE AGED; PATHOLOGY; SKIN TUMOR;

AGED; B7-H1 ANTIGEN; CASE-CONTROL STUDIES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MELANOMA; MIDDLE AGED; NEOPLASM INVASIVENESS; SKIN NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 85010904845     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2016.210     Document Type: Article

References (36)

1. Chen LL, Jaimes N, Barker CA, et al. Desmoplastic melanoma: A review. J Am Acad Dermatol 2013;68: 825-833.
2. Feng Z, Wu X, Chen V, et al. Incidence and survival of desmoplastic melanoma in the United States, 1992-2007. J Cutan Pathol 2011;38:616-624.
3. Busam KJ, Mujumdar U, Hummer AJM, et al. Cutaneous desmoplastic melanoma: reappraisal of morphologic heterogeneity and prognostic factors. J Surg Pathol 2004;28:1518-1525.
4. Hawkins WG, Busam KJ, Ben-Porat L, et al. Desmoplastic melanoma: A pathologically and clinically distinct form of cutaneous melanoma. Ann Surg Oncol 2005;12:207-213.
5. George E, McClain SE, Slingluff CL, et al. Subclassification of desmoplastic melanoma: pure and mixed variants have significantly different capacities for lymph node metastasis. J Cutan Pathol 2009;36: 425-432.
6. Miller DD, Emley A, Yang S, et al. Mixed versus pure variants of desmoplastic melanoma: A genetic and immunohistochemical appraisal. Mod Pathol 2012;25: 505-515.
7. Frydenlund N, Leone DA, Mitchell B, et al. Neurotrophin receptors and perineural invasion in desmoplastic melanoma. J Am Acad Dermatol 2015;72: 851-858.
8. Kadokura A, Frydenlund N, Leone DA, et al. Neurofibromin protein loss in desmoplastic melanoma subtypes: implicating NF1 allelic loss as a distinct genetic driver Hum Pathol 2016;53:82-90.
9. Yang S, Leone D, Frydenlund N, et al. Frequency of telomerase reverse transcripter promoter mutations in desmoplastic melanoma subtypes: Analyses of 76 cases. Melanoma Res 2016;26:361-366.
10. Jahn SW, Kashofer K, Halbwedl I, et al. Mutational dichotomy in desmoplastic malignant melanoma corroborated by multigene panel analysis. Mod Pathol 2015;28:895-903.
11. Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev 2010;236:219-242.
12. Llosa NJ, Cruise M, Tam A, et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov 2015;5:43-51.
13. Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015;372:320-330.
14. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-2454.
15. Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015;372:2521-2532.
16. Herbst RS, Soria J-C, Kowanetz M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014;515: 563-567.
17. Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014;515:568-571.
18. Taube JM, Klein A, Brahmer JR, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Am Assoc Cancer Res 2014;20:5064-5074.
19. Eroglu Z, Kim DW, Johnson DB, et al. Response to anti-PD1/PDL1 therapy in patients with metastatic desmoplastic melanoma. ASCO Meet Abstr 2015;33: 9011.
20. Rodi N, Anders RA, Eshleman JR, et al. PD-L1 expression in melanocytic lesions does not correlate with the BRAF V600E mutation. Cancer Immunol Res 2015;3:110-115.
21. Shain AH, Garrido M, Botton T, et al. Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway. Nat Genet 2015;47: 1194-1199.
22. Rabbie R, Adams DJ. Desmoplastic melanoma: C4Ts and NFB. Pigment Cell Melanoma Res 2016;29:120-121.
23. Snyder A, Makarov V, Merghoub T, et al. genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 2014;371:2189-2199.
24. Allen EMV, Miao D, Schilling B, et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 2015;350:207-211.
25. Madore J, Strbenac D, Vilain R, et al. PD-L1 negative status is associated with lower mutation burden, differential expression of immune-related genes, and worse survival in stage III melanoma. Am Assoc Cancer Res 2016;22:3915-3923.
26. Kakavand H, Vilain RE, Wilmott JS, et al. Tumor PD-L1 expression, immune cell correlates and PD-1+ lymphocytes in sentinel lymph node melanoma metastases. Mod Pathol 2015;28:1535-1544.
27. Madore J, Vilain RE, Menzies AM, et al. PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials. Pigment Cell Melanoma Res 2015;28:245-253.
28. Thierauf J, Veit JA, Affolter A, et al. Identification and clinical relevance of PD-L1 expression in primary mucosal malignant melanoma of the head and neck. Melanoma Res 2015;25:503-509.
29. Taube JM, Anders RA, Young GD, et al. Colocalization of inflammatory response with B7-H1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 2012;4:127ra37-127ra37.
30. Hino R, Kabashima K, Kato Y, et al. Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer 2010;116:1757-1766.
31. Massi D, Brusa D, Merelli B, et al. The status of PD-L1 and tumor-infiltrating immune cells predict resistance and poor prognosis in BRAFi-treated melanoma patients harboring mutant BRAFV600. Ann Oncol 201526: 1980-1987.
32. Massi D, Brusa D, Merelli B, et al. PD-L1 marks a subset of melanomas with a shorter overall survival and distinct genetic and morphological characteristics. Ann Oncol 2014;25:2433-2442.
33. Frydenlund N, Mahalingam M. Desmoplastic melanoma, neurotropism, and neurotrophin receptors-what we know and what we do not. Adv Anat Pathol 2015;22:227-241.
34. Larkin J, Hodi FS, Wolchok JD. Combined Nivolumab and Ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015;373:1270-1271.
35. Weber JS, Kudchadkar RR, Yu B, et al. Safety, efficacy, and biomarkers of Nivolumab with vaccine in Ipilimumab-refractory or-naive melanoma. J Clin Oncol 2013;31:4311-4318.
36. Latchman Y, Wood CR, Chernova T, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2001;2:261-268.